Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv

Citations Over TimeTop 19% of 2001 papers

Abstract

This is the first report using scFv-targeting immunolipoplexes for systemic gene therapy. The TfRscFv has a number of advantages over the transferrin (Tf) molecule itself: (1) scFv has a much smaller size than Tf producing a smaller immunolipoplex giving better penetration into solid tumors; (2) unlike Tf, the scFv is a recombinant protein, not a blood product; (3) large scale production and strict quality control of the recombinant scFv, as well as scFv-immunolipoplex, are feasible. The sensitization of tumors to chemotherapy by this tumor-targeted and efficient p53 gene delivery method could lower the effective dose of the drug, correspondingly lessening the severe side effects, while decreasing the possibility of recurrence. Moreover, this approach is applicable to both primary and recurrent tumors, and more significantly, metastatic disease. The TfRscFv-targeting of cationic immunolipoplexes is a promising method of tumor targeted gene delivery that can be used for systemic gene therapy of cancer with the potential to critically impact the clinical management of cancer.

Related Papers

• → Transferrin receptor 2: a new molecule in iron metabolism(2003)93 cited
• → Lymphocyte Proliferation Is Controlled by both Iron Availability and Regulation of Iron Uptake Pathways(1992)68 cited
• → [22] Receptor assay with radiolabeled transferrin(1987)13 cited
• → Species specificity of iron delivery in hybridomas(1988)11 cited
• → Commentary: Mutations of Transferrin Receptor 2 (Trf-2) and Iron Storage Disease(2001)2 cited